Medicago, GSK start phase III of COVID-19 vaccine trial

By The Science Advisory Board staff writers

Medicago and GlaxoSmithKline (GSK) have started phase III of their adjuvanted COVID-19 vaccine candidate clinical trial.

This portion of the trial will enroll 30,000 volunteers from 10 countries, according to the two firms. The vaccine candidate uses coronavirus-like-particle technology; two doses of 3.75 µg are administered three weeks apart. The drug has been granted "fast track" designation by the U.S. Food and Drug Administration (FDA).

Medicago has also begun a feasibility study of a vaccine candidate for emerging COVID-19 variants, it said.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking